Alumis (United States) Overview
- Year Founded
-
2021
- Status
-
Public
- Employees
-
239
- Stock Symbol
-
ALMS
- Investments
-
2
- Share Price
-
$6.13
- (As of Thursday Closing)
Alumis (United States) General Information
Description
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Contact Information
Website
www.alumis.comCorporate Office
- 280 East Grand Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 280 East Grand Avenue
- South San Francisco, CA 94080
- United States
Alumis (United States) Timeline
Alumis (United States) Stock Performance
As of 12-Nov-2026, Alumis (United States)’s stock price is $6.13. Its current market cap is $796M with 130M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.13 | $6.62 | $4.60 - $31.35 | $796M | 130M | 2.79M | -$3.53 |
Alumis (United States) Financials Summary
As of 30-Sep-2026, Alumis (United States) has a trailing 12-month revenue of $7.24M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 490,660 | 678,953 | 96,870 | |
| Revenue | 7,239 | 24,050 | 0 | 0 |
| EBITDA | (439,496) | (262,570) | (303,101) | (157,077) |
| Net Income | (423,086) | (243,325) | (294,233) | (154,993) |
| Total Assets | 488,711 | 411,940 | 340,992 | 89,612 |
| Total Debt | 35,306 | 36,914 | 30,722 | 32,580 |
Alumis (United States) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alumis (United States) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Alumis (United States) Comparisons
Industry
Financing
Details
Alumis (United States) Competitors (2)
One of Alumis (United States)’s 2 competitors is Kyverna, a Formerly VC-backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kyverna | Formerly VC-backed | Emeryville, CA | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA |
Alumis (United States) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alumis (United States) Patents
Alumis (United States) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222314-A1 | Tyk2 inhibitors for use in the treatment of neurodegenerative diseases | Pending | 18-Apr-2025 | ||
| WO-2026136251-A1 | Tyk2 inhibitor for treating neuroinflammatory or neurodegenerative diseases | Pending | 16-Dec-2024 | ||
| WO-2026136251-A9 | Tyk2 inhibitor for treating neuroinflammatory or neurodegenerative diseases | Pending | 16-Dec-2024 | ||
| WO-2026128621-A3 | Process of making a tyk2 inhibitor and intermediates thereof | Pending | 12-Dec-2024 | ||
| WO-2026128621-A2 | Process of making tyk2 inhibitors and uses thereof | Pending | 12-Dec-2024 | C07D401/12 |
Alumis (United States) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alumis (United States) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alumis (United States) Acquisitions (2)
Alumis (United States)’s most recent deal was a Merger/Acquisition with Acelyrin for . The deal was made on 21-May-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Acelyrin | 21-May-2025 | Merger/Acquisition | Drug Discovery | ||
| FronThera US Holdings | 05-Mar-2021 | Merger/Acquisition | Drug Discovery |
Alumis (United States) ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Alumis (United States) FAQs
-
When was Alumis (United States) founded?
Alumis (United States) was founded in 2021.
-
Where is Alumis (United States) headquartered?
Alumis (United States) is headquartered in South San Francisco, CA.
-
What is the size of Alumis (United States)?
Alumis (United States) has 239 total employees.
-
What industry is Alumis (United States) in?
Alumis (United States)’s primary industry is Drug Discovery.
-
Is Alumis (United States) a private or public company?
Alumis (United States) is a Public company.
-
What is Alumis (United States)’s stock symbol?
The ticker symbol for Alumis (United States) is ALMS.
-
What is the current stock price of Alumis (United States)?
As of 12-Nov-2026 the stock price of Alumis (United States) is $6.13.
-
What is the current market cap of Alumis (United States)?
The current market capitalization of Alumis (United States) is $796M.
-
What is Alumis (United States)’s current revenue?
The trailing twelve month revenue for Alumis (United States) is $7.24M.
-
Who are Alumis (United States)’s competitors?
Kyverna and Aclaris Therapeutics are competitors of Alumis (United States).
-
What is Alumis (United States)’s annual earnings per share (EPS)?
Alumis (United States)’s EPS for 12 months was -$3.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
